

## Kişisel Bilgiler

E-posta: arifakyildiz@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/arifakyildiz>

## SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)**  
AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., Aslan F., SÜTCÜOĞLU O., YAZICI O., Kadioglu A., et al.  
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, sa.9, ss.4991-4999, 2024 (SCI-Expanded)
- II. **Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine**  
ŞAHİN T. K., AKYILDIZ A., DOĞAN O. T., KAVGACI G., GÜVEN D. C., AKSOY S.  
PHARMACEUTICALS, sa.7, 2024 (SCI-Expanded)
- III. **Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group**  
AKYILDIZ A., GÜLTEKİN M., YİĞİT E., Demir E., Ismayilov R., AHMED M. A., Buyukkor M., YILDIRIM H. Ç., Yildirim N., Ucar G., et al.  
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024 (SCI-Expanded)
- IV. **Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab**  
YILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., Ceyhan F., Kavruk O., GÜVEN D. C., Ates O., et al.  
BIOMOLECULES AND BIOMEDICINE, sa.4, ss.998-1003, 2024 (SCI-Expanded)
- V. **Comprehensive analysis of orbital lymphoma in a Turkish cohort: clinical characteristics, histological subtypes, treatment modalities, prognostic factors, and implications for management**  
AKYILDIZ A., Ismayilov R., Rustamova N., Tokatli M., KOÇ İ., AKIN S., KIRATLI H., BARIŞTA İ.  
Annals of Hematology, cilt.103, sa.3, ss.905-915, 2024 (SCI-Expanded)
- VI. **Sirolimus experience in adult patients with vascular malformations**  
AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., Chalabiyev E., TÜRKER F. A., DİZDAR Ö., YALÇIN Ş., et al.  
Vascular, 2024 (SCI-Expanded)
- VII. **A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology**  
YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.  
Irish Journal of Medical Science, cilt.192, sa.6, ss.2631-2634, 2023 (SCI-Expanded)
- VIII. **The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey**  
AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., YILDIZ İ., Iriagac Y., Turhal S., Akbas S., et al.  
Medicine, cilt.102, sa.45, 2023 (SCI-Expanded)
- IX. **A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer**  
YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., YALÇIN Ş.

Anti-cancer drugs, cilt.34, sa.10, ss.1190-1192, 2023 (SCI-Expanded)

- X. **Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group**  
Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., YALÇIN Ş., Çoban E., EVRENSEL T., Kalkan Z., et al.  
The oncologist, cilt.28, sa.10, ss.875-884, 2023 (SCI-Expanded)
- XI. **Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort**  
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., Chalabiyev E., KUŞ F., YALÇIN Ş., AKSOY S.  
Medicine (United States), cilt.102, sa.18, 2023 (SCI-Expanded)
- XII. **KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer**  
KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., ŞAHİN Y., Ileri S., Karaca E., KERTMEN N., et al.  
Biomarkers in Medicine, cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded)
- XIII. **Emerging treatment strategies in hepatobiliary cancer**  
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., AKYILDIZ A., AKTAŞ B. Y., YALÇIN Ş., DİZDAR Ö.  
Expert Review of Anticancer Therapy, cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded)

## Diğer Dergilerde Yayınlanan Makaleler

- I. **Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye**  
Unal C., Selcuk N. A., Biricik F. S., Alan O., Ordu C., Selvi O., Sakin A., Sever N., Topcu Z. A., AKYILDIZ A., et al.  
Eurasian Journal of Medicine and Oncology, cilt.7, sa.3, ss.232-242, 2023 (ESCI)
- II. **Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer**  
YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., AKYILDIZ A., YILMAZ F., YAŞAR S., Evlendi Y., et al.  
Journal of Oncological Science, cilt.9, sa.1, ss.33-37, 2023 (Scopus)
- III. **Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review**  
YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., AKIN S., YALÇIN Ş., BARIŞTA İ.  
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, cilt.15, sa.4, ss.307-310, 2022 (ESCI)
- IV. **Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy**  
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., KUŞ F., AKYILDIZ A., GÜRBÜZ S. Ç., Sayin H., et al.  
Journal of Oncological Science, cilt.8, sa.3, ss.143-147, 2022 (Scopus)

## Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **The efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: A multicenter study by the Turkish Oncology Group (TOG)**  
Akyildiz A., GÜLTEKİN M., Yigit E., Demir E., Ismayilov R., AHMED M. A., Buyukkor M., Yildirim H. C., Yildirim N., Algin E., et al.  
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024
- II. **Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic**

**head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).**

Akyildiz A., Guven D. C., Koksall B., Karaoglan B. B., Salim D. K., Sutcuoglu O., Erciyestepe M., Alan O., Taban H., Yildirim N., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024

## **Metrikler**

Yayın: 19